Back to Journals » Drug Design, Development and Therapy » Volume 7

Novel phytochemical–antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR

Authors Jayaraman P, Sakharkar KR, Lim C, Siddiqui MI, Dhillon SK, Sakharkar MK

Received 12 February 2013

Accepted for publication 2 April 2013

Published 17 June 2013 Volume 2013:7 Pages 449—475

DOI https://doi.org/10.2147/DDDT.S43964

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Premkumar Jayaraman,1,2 Kishore R Sakharkar,3 ChuSing Lim,1,2 Mohammad Imran Siddiqi,4 Sarinder K Dhillon,5 Meena K Sakharkar1,6

1
Biomedical Engineering Research Centre, Nanyang Technological University, Singapore; 2Advanced Design and Modeling Lab, Nanyang Technological University, Singapore; 3OmicsVista, Singapore; 4Molecular and Structural Biology Division, Central Drug Research Institute, India; 5Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia; 6School of Life and Environmental Sciences, University of Tsukuba, Ibaraki, Japan

Background: There is a dearth of treatment options for community-acquired and nosocomial Pseudomonas infections due to several rapidly emerging multidrug resistant phenotypes, which show resistance even to combination therapy. As an alternative, developing selective promiscuous hybrid compounds for simultaneous modulation of multiple targets is highly appreciated because it is difficult for the pathogen to develop resistance when an inhibitor has activity against multiple targets.
Methods: In line with our previous work on phytochemical–antibiotic combination assays and knowledge-based methods, using a fragment combination approach we here report a novel drug design strategy of conjugating synergistic phytochemical–antibiotic combinations into a single hybrid entity for multi-inhibition of P. aeruginosa DNA gyrase subunit B (GyrB)/topoisomerase IV subunit B (ParE) and dihydrofolate reductase (DHFR) enzymes. The designed conjugates were evaluated for their multitarget specificity using various computational methods including docking and dynamic simulations, drug-likeness using molecular properties calculations, and pharmacophoric features by stereoelectronic property predictions.
Results: Evaluation of the designed hybrid compounds based on their physicochemical properties has indicated that they are promising drug candidates with drug-like pharmacotherapeutic profiles. In addition, the stereoelectronic properties such as HOMO (highest occupied molecular orbital), LUMO (lowest unoccupied molecular orbital), and MEP (molecular electrostatic potential) maps calculated by quantum chemical methods gave a good correlation with the common pharmacophoric features required for multitarget inhibition. Furthermore, docking and dynamics simulations revealed that the designed compounds have favorable binding affinity and stability in both the ATP-binding sites of GyrB/ParE and the folate-binding site of DHFR, by forming strong hydrogen bonds and hydrophobic interactions with key active site residues.
Conclusion: This new design concept of hybrid “phyto-drug” scaffolds, and their simultaneous perturbation of well-established antibacterial targets from two unrelated pathways, appears to be very promising and could serve as a prospective lead in multitarget drug discovery.

Keywords: hybrid compounds, multi-target inhibition, drug resistance, dihydrofolate reductase, DNA gyrase subunit B, topoisomerase IV subunit B, rational drug design

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]